Experienced in Acrocephalopolydactyly

Daniel C. Betticher

Fribourg, FR, CH 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Acrocephalopolydactyly
Fribourg, FR, CH 
OverviewLocationsClinical Research

Overview

Daniel Betticher practices in Fribourg, Switzerland. Mr. Betticher is rated as an Experienced expert by MediFind in the treatment of Acrocephalopolydactyly. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, and Multiple Myeloma.

His clinical research consists of co-authoring 64 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Acrocephalopolydactyly.

Gender
Male

Locations

Fribourg, FR, Switzerland
Other Locations
Geneve, GE 1205, Switzerland
Bern, BE, Switzerland
Villars, JU 1752, Switzerland
Kantonsspital
Luzern, LU, Switzerland
Sankt Gallen, SG, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Multicentre Single Arm Phase II Trial Assessing the Efficacy of Immunotherapy, Chemotherapy and Stereotactic Radiotherapy to Metastases Followed by Definitive Surgery or Radiotherapy to the Primary Tumour, in Patients With Synchronous Oligo-metastatic Non-small Cell Lung Cancer
A Multicentre Single Arm Phase II Trial Assessing the Efficacy of Immunotherapy, Chemotherapy and Stereotactic Radiotherapy to Metastases Followed by Definitive Surgery or Radiotherapy to the Primary Tumour, in Patients With Synchronous Oligo-metastatic Non-small Cell Lung Cancer
Enrollment Status: Recruiting
Publish Date: February 03, 2025
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Durvalumab, Carboplatin, Paclitaxel
Study Phase: Phase 2
First Line Durvalumab in Patients With PD-L1 Positive, Advanced NSCLC With Performance Status 2 Unsuitable for Combination Chemotherapy. A Multicenter, Single-arm Phase II Trial
First Line Durvalumab in Patients With PD-L1 Positive, Advanced NSCLC With Performance Status 2 Unsuitable for Combination Chemotherapy. A Multicenter, Single-arm Phase II Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 15, 2025
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
A Single Arm Phase II Trial Evaluating the Activity of Alectinib for the Treatment of Pretreated RET-rearranged Advanced NSCLC
A Single Arm Phase II Trial Evaluating the Activity of Alectinib for the Treatment of Pretreated RET-rearranged Advanced NSCLC
Enrollment Status: Terminated
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drug: Alectinib
Study Phase: Phase 2
Assessing a Circulating Tumor (ctDNA) and Positron Emission Tomography (PET)-Oriented Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL). A Multicenter, Open-label, Phase II Trial.
Assessing a Circulating Tumor (ctDNA) and Positron Emission Tomography (PET)-Oriented Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL). A Multicenter, Open-label, Phase II Trial.
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drug: Acalabrutinib
Study Phase: Phase 2
A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC
A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Other, Drug
Study Phase: Phase 3
Anti-PD-L1 Antibody MEDI4736 in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC). A Multicenter Single-arm Phase II Trial.
Anti-PD-L1 Antibody MEDI4736 in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC). A Multicenter Single-arm Phase II Trial.
Enrollment Status: Completed
Publish Date: April 15, 2024
Intervention Type: Drug
Study Drug: MEDI4736
Study Phase: Phase 2
Fibroblast Growth Factor Receptor (FGFR) Inhibitor Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) Overexpressing FGFR mRNA. A Multicenter, Single Arm Phase II Trial
Fibroblast Growth Factor Receptor (FGFR) Inhibitor Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) Overexpressing FGFR mRNA. A Multicenter, Single Arm Phase II Trial
Enrollment Status: Terminated
Publish Date: November 09, 2022
Intervention Type: Drug
Study Drug: Rogaratinib
Study Phase: Phase 2
A Phase II Trial Evaluating the Safety and Efficacy of the Addition of Concurrent Anti-PD 1 Nivolumab to Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
A Phase II Trial Evaluating the Safety and Efficacy of the Addition of Concurrent Anti-PD 1 Nivolumab to Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
Enrollment Status: Completed
Publish Date: August 24, 2022
Intervention Type: Drug
Study Phase: Phase 2
Prospective Cohort Study With Collection of Clinical Data, Serum and Plasma of Patients With Prostate Disease
Prospective Cohort Study With Collection of Clinical Data, Serum and Plasma of Patients With Prostate Disease
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2022
Intervention Type: Other
Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma. A Multi-center, Single Arm Phase II Trial
Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma. A Multi-center, Single Arm Phase II Trial
Enrollment Status: Terminated
Publish Date: June 10, 2021
Intervention Type: Drug
Study Drugs: Pomalidomide, Dexamethasone
Study Phase: Phase 2
Implementation of the Symptom Navi© Program for Cancer Patients in Ambulatory Services: A Cluster-randomized Pilot Study (Symptom Navi© Pilot Study)
Implementation of the Symptom Navi© Program for Cancer Patients in Ambulatory Services: A Cluster-randomized Pilot Study (Symptom Navi© Pilot Study)
Enrollment Status: Completed
Publish Date: August 24, 2020
Intervention Type: Behavioral
Study Phase: Not Applicable
Early Prophylactic Cranial Irradiation With Hippocampal Avoidance in Patients With Limited Disease Small-cell Lung Cancer. A Multicenter Phase II Trial
Early Prophylactic Cranial Irradiation With Hippocampal Avoidance in Patients With Limited Disease Small-cell Lung Cancer. A Multicenter Phase II Trial
Enrollment Status: Completed
Publish Date: January 29, 2020
Intervention Type: Radiation
Study Phase: Not Applicable
View 11 Less Clinical Trials

64 Total Publications

Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature.
Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature.
Journal: Swiss medical weekly
Published: January 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Betticher's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile